MTOR and diffuse large B-cell lymphoma: Here, we applied this approach to determine whether post-transcriptional regulation mediated by lncRNAs might be an additional layer to quickly control protein expression in diffuse large B cell lymphoma (DLBCL) cells exposed to bimiralisib, a dual PI3K/mTOR inhibitor with proven preclinical and early clinical anti-lymphoma activity [8,9].